Pro-IV

Company Overview

Snapshot

Founded in November 2006 by Jacob Nusbacher, Pierre Sharvit, Gershon Goldenberg, and Michal Devir, Pro-IV operates with 1–10 employees. The company raised $415,000 across one funding round from one investor. Pro-IV ceased operations in October 2020.

Business overview

Pro-IV developed a mobile platform for managing and monitoring patients receiving infusion therapy at home or in clinical settings. Its core technology, the Intravenous Monitoring, Management, and Error-prevention (IMMAGINE) system, aims to enhance patient safety by reducing bedside errors in IV drug therapy and blood transfusions. The system also improves the accuracy, monitoring, and documentation of electronic patient data. Pro-IV serves the healthcare industry, specifically targeting providers and patients, and operates within the Health Tech & Life Sciences sector, focusing on Digital Healthcare and Patient Remote Monitoring.

Company Intelligence Q&A

What is Pro-IV's primary focus?

Pro-IV focuses on developing mobile platforms to monitor, manage, and prevent infusion and transfusion errors in patients, both at home and in hospitals.

When was Pro-IV founded and by whom?

Pro-IV was founded in November 2006 by Jacob Nusbacher, Pierre Sharvit, Gershon Goldenberg, and Michal Devir.

What is the IMMAGINE system?

The IMMAGINE (Intravenous Monitoring, Management, and Error-prevention) system is Pro-IV's core product designed to significantly reduce errors and save lives by improving bedside management and error prevention for patients receiving IV drug therapy or blood transfusions.

What was a notable early investment in Pro-IV?

In October 2006, Pro-IV received a NIS 1.5 million investment, as reported by Globes.

What is the current status of Pro-IV?

Pro-IV is currently non-active, having ceased operations in October 2020.